Intensity Therapeutics, Inc. (INTS) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 31.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: N/A
• EPS Growth: -48.92%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 15,180,945
• 10 Day Avg. Volume: 21,139
• 30 Day Avg. Volume: 31,809
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 95.42
• Price to Cash Flow (P/CF): -2.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.25
• Price Target Upside: 212.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Intensity Therapeutics' stock score reflects its developmental stage as a biotechnology firm with no revenue, reliance on external funding, and negative profit margins. The technical indicators suggest bearish sentiment, while the valuation metrics highlight the speculative nature of the stock. The score is primarily influenced by the company's financial performance challenges and bearish technical analysis.

Positive Factors

Clinical Trials

DOR data bodes well for the Phase 3 sarcoma study.

Product Potential

INT230-6 provides an attractive approach to treat solid tumors where there is an unmet need due to limited penetration of chemotherapy into the TME.

Negative Factors

Financial Performance

The company reported no revenues, and a net loss of $0.25 per diluted share, compared to our estimate of no revenues and a net loss of $0.16 per diluted share.

Intensity Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Intensity Therapeutics, Inc. (INTS) is a biotechnology company focused on the development of novel cancer treatment therapies. The company specializes in the creation of proprietary drug formulations that are designed to enhance the delivery and efficacy of cancer treatments. Through its innovative approach, Intensity Therapeutics aims to improve patient outcomes by effectively targeting and eliminating cancer cells while minimizing damage to healthy tissue.

How the Company Makes Money

Intensity Therapeutics, Inc. makes money primarily through the development and commercialization of its proprietary cancer treatment therapies. The company generates revenue from the sale of its drug formulations, which are designed to be used in combination with existing cancer treatment regimes. Additionally, Intensity Therapeutics may enter into strategic partnerships or licensing agreements with pharmaceutical companies, allowing them to expand the reach of their therapies and receive milestone payments and royalties. The company may also receive funding through grants or investments from private and public sources to support its research and development efforts.

Intensity Therapeutics, Inc. Financial Statement Overview

Summary

Intensity Therapeutics is in its early development stages, typical of biotechnology firms with no revenue generation yet. The company is heavily reliant on external financing to support its R&D operations, as reflected in the financial metrics. Negative profit margins and cash flow figures highlight the financial challenges faced, yet its cash position offers some short-term stability. Investors should focus on the company's progress toward revenue generation and managing its cash reserves effectively.

Income Statement

Intensity Therapeutics has consistently reported zero revenue, indicating a company still in the development phase typical of biotechnology firms. The net profit margins are negative due to ongoing operational expenses without offsetting revenue. EBIT and EBITDA margins are also negative, highlighting the company's high expenditure relative to nonexistent revenue. Revenue and profit growth are absent, reflecting the company's pre-revenue stage.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio due to negative equity, which is typical for companies incurring losses during their R&D phase. Stockholders' equity is negative, indicating liabilities exceed assets. However, cash reserves are sufficient to cover immediate liabilities, which is a positive aspect for liquidity. The equity ratio is not a useful measure here given the negative equity.

Cash Flow

Operating cash flow remains negative, reflecting the cash burn typical for biotech firms in R&D. There is no free cash flow growth due to ongoing operational losses. The financing activities indicate reliance on external funding to support operations. Cash flow ratios are not meaningful due to negative income and free cash flow.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-147.00K	-179.04K	0.00	0.00
	EBIT
-16.59M	-8.32M	-7.63M	-8.01M	-6.22M
	EBITDA
-16.59M	-10.09M	-7.40M	-7.88M	-6.03M
	Net Income Common Stockholders
-16.27M	-10.54M	-7.45M	-7.89M	-5.96M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.59M	14.78M	1.31M	4.54M	9.32M
	Total Assets
4.78M	17.30M	1.76M	5.22M	10.15M
	Total Debt
138.00K	158.00K	4.49M	2.34M	497.48K
	Net Debt
-2.45M	-8.40M	3.18M	-2.20M	-8.82M
	Total Liabilities
1.86M	4.13M	16.85M	13.90M	11.71M
	Stockholders Equity
2.92M	13.16M	-15.10M	-8.68M	-1.56M
Cash Flow		Free Cash Flow
-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
	Operating Cash Flow
-15.22M	-7.21M	-5.48M	-6.83M	-5.37M
	Investing Cash Flow
6.35M	-6.02M	0.00	0.00	4.56M
	Financing Cash Flow
2.90M	20.47M	2.25M	2.05M	6.29M

Intensity Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Negative. The current price of 2 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.19, and below the 200-day MA of 3.27, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 40.69 is Neutral, neither overbought nor oversold. The STOCH value of 24.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTS.

Intensity Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
TCRT	47 Neutral	$6.76M	―	-111.83%	―	80.00%	86.70%
BDRX	45 Neutral	$802.31K	―	-96.61%	―	-83.72%	99.56%
ONCO	33 Underperform	$1.10M	―	-233.77%	―	―	-97.16%
INTS	32 Underperform		―	-202.34%	―	―	-48.92%
SLRX	26 Underperform	$1.22M	―	-164.02%	―	―	79.57%